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Abstract: 
Migraine is a highly disabling neurological condition affecting around 15% of the population worldwide. 
Decades of intensive research shed some light on diseases pathomechanism, but information is still missing 
about the initiation of the attack. In the past century, serotonin emerged as the main target of both basic and 
therapeutic research. As a result, the triptans, the only approved migraine specific drugs were developed. The 
involvement of glutamatergic mechanism in migraine headache development such as cortical hyperexcitability, 
and cortical spreading depression as the pathological correlate of migraine aura called the attention to the 
kynurenine pathway in migraine pathomechanism. The serotonin and kynurenine pathways are closely 
connected, as they both are the metabolic routes of the amino acid tryptophan. Kynurenine catabolites are 
important participants in glutamatergic neurotransmission, regulation also nociceptive processing of the 
trigeminal system. The current work attempts to collect recent data on both serotonin and kynurenine research 
related to migraine and emphasizes the importance of further research on this topic. 
 







Migraine is a common neurological disorder with a one-year prevalence of 14.7% [1]. Despite intensive 
research the exact pathomechanism of the disease is still not completely understood. The importance of migraine 
research is clearly shown by the fact that migraine is the sixth highest cause of disability worldwide, and together 
the headache disorders are the third on the list of causes of disability [2]. 
Based on data so far, migraine can be considered as a painful multifactorial disorder [3], involving autonomic, 
affective, cognitive and sensory functions. Glutamate and serotonin mediated neurotransmission both play an 
important role in the evolution of migraine headaches [4]. The kynurenine pathway (KP), the main route of 
tryptophan metabolism, is closely involved with both glutamatergic and serotonergic mechanisms placing the 
catabolites of this pathway under spotlight in migraine research [5]. The scope of our review is to highlight the 
possible connections of the KP with processes involved in migraine pathomechanism. 
 
2. METABOLISM OF TRYPTOPHAN 
In mammals, the excess of tryptophan not necessary for protein synthesis is utilized either for the synthesis of 
the important neurotransmitters serotonin (5-hydroxytryptamine, 5HT) and melatonin (N-acetyl-5-
methoxytrypamine) or is oxidized via the KP. In humans more than 90% of dietary tryptophan is metabolized via 
the KP at the periphery [6]. Both metabolic routes include important neuroactive catabolites with a possible role 
in the pathomechanism of migraine headache. 
 
2.1 The Kynurenine Pathway 
The first, rate-limiting step of the kynurenine pathway (KP) is the irreversible cleavage of the indole ring of 
L-tryptophan (TRP) either by indoleamine 2,3-dioxygenase 1 and 2 (IDO1 and 2), or by tryptophan 2,3-
dioxygenase (TDO) (Figure 1). 
IDO1 can be found throughout the body, and functions as a monomeric protein. Besides TRP, it can also 
utilize D-tryptophan, 5-hydroxy-L-kynurenine, 5-hydroxy-D-kynurenine, melatonin [7] and serotonin [8].  
Less is known about IDO2, since it was isolated less than 10 years ago [9]. Data gathered so far indicate that 
the expression of IDO2 is not as widespread as that of IDO1, and that this enzyme may influences immune 
regulation differently than IDO1 [10]. TDO functions as a homotetramer and contains a heme B group. It is 
expressed predominantly in the liver, but can also be found in the brain and placenta [11, 12]. TDO is more 
substrate specific than IDO 1, claiming only L-tryptophan for metabolism [13]. 
Reactions catalyzed by either enzymes result in the formation of N-formyl-L-kynurenine, which is further 
degraded by kynurenine formamidase to L-kynurenine (L-KYN), the central metabolite of the KP. From L-KYN 
the kynurenine aminotransferases (KATs) form kynurenic acid (KYNA), kynureninase forms anthranilic acid 
(AA), while kynurenine 3-monooxygenase (KMO) activity results in the formation of 3-hydroxykynurenine 
(3HK). In mammals four type of KATs are present, KAT I also known as glutamine transaminase K/cysteine 
conjugate beta-lyase I [14, 15], KAT II/aminoadipate aminotransferase [16, 17], KAT III/cysteine conjugate 
beta-lyase II [18] and KAT IV/glutamic-oxaloacetic transaminase 2/mitochondrial aspartate aminotransferase 
[19, 20]. All of the KATs are able to metabolize L-KYN to KYNA, however their substrate specificity, 
metabolic rate and expression are different [21].  
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Kynureninase is a pyridoxal-5’-phosphate dependent enzyme, it is able to catalyze two reactions along the KP 
it converts L-KYN to AA and it promotes the conversion of 3HK to 3-hydroxyanthranilic acid (3HA). The first 
mechanism is common in prokaryotes while in eukaryotes the latter pathway is preferred, therefore in mammals 
the conversion of L-KYN proceeds either to the KYNA or to the 3HK route [22]. 
AA is further metabolized by anthranilae-3-monooxygenase to 3HA, while from 3HK kynureninase forms the 
same compound. 3HK can be also converted by KATs to xanthurenic acid. 3HA is either subjected to auto 
oxidation resulting in cinnabarinic acid, or it is converted to 2-amino-3-carboxymuconate semialdehyde (ACMS) 
by 3-hydroxyanthranilic acid oxygenase. ACMS can be further processed by aminocarboxymuconate-
semialdehyde decarboxylase to 2-aminomuconate semialdehyde, followed by a non-enzymatic transformation to 
picolinic acid. ACMS can also undergo spontaneous pyridine ring closure to form quinolinic acid (QUIN), which 
can be further processed to form nicotinamide adenine dinucleotide. 
 
2.2 Serotonin pathway 
The first rate-limiting step in the synthesis of 5HT is the hydroxylation of L-tryptophan by the enzyme 
tryptophan hydroxylase (TPH) and results in the formation of 5-hydroxytryptophan. This metabolite is 
transformed by aromatic amino acid decarboxylase (AADA) to 5HT. Metabolism of 5HT by monoamine oxidase 
(MAO) to 5-hydroxyindole acetaldehyde and further by aldehyde dehydrogenase, results in the end product 5-
hydroxyindoleacetic acid (5HIAA), which is generally used to indirectly detect changes in serotonin levels. In 
the pineal gland and in the retina 5HT is metabolized by serotonin N-acetyltransferase to N-acetylserotonin, 
which is further converted by hydroxyindole-O-methyltransferase to melatonin. 
 
2.3 Receptorial and non-receptorial actions of tryptophan catabolites 
Several kynurenine catabolites were shown to have direct receptorial actions. L-KYN, KYNA and 
cinnabarinic acid are ligands of aryl hydrocarbon receptors (AHRs) [23-25]. AHR is a nuclear transcription 
factor regulating the expression of genes of xenobiotic metabolizing enzymes, such as cytochrome P450 protein 
and glutathione transferase. This receptor possesses important functions in immune regulation, and T-cell 
development [26] . 
KYNA is an endogenous ionotropic glutamate receptor antagonist, acting on N-methyl-D-aspartate (NMDA) 
receptors at both the strychnine-insensitive glycine site and on the glutamate recognition site [27, 28]. In addition 
it is also an antagonist  of kainate glutamate receptors [29], while it has a Janus-face effect on α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, in nanomolar concentration it has a 
facilitatory, while in micromolar concentration an inhibitory effect on these receptor [30-32]. KYNA’s broad 
receptorial action indicates that it has a very important role in the regulation of glutamatergic neurotransmission. 
This regulatory role is further supported by the fact that KYNA is an antagonist of α7-nicotinic acetylcholine 
(α7nACh) receptors, thus is able to modulate presynaptic glutamate release [33]. KYNA also has weak agonistic 
effects on the G protein coupled receptor 35 (GPCR 35) [34].  
QUIN is a weak endogenous agonist of NMDA receptors [35], while cinnabarinic acid acts on type 4 
metabotropic glutamate receptors [36]. 
Besides the direct receptorial actions of tryptophan catabolites, they also participate on oxidative processes, 
and thus are important factors in mitochondrial energy metabolism [37].  
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The effects of 5HT are transmitted by 7 receptor subtypes, 5HT1-7 receptors. Throughout them 5HT exerts 
myriad of functions, modulating mood, memory, appetite and circadian rhythms. With one exception, 5HT3, 
which is a ligand gated cation channel, 5HT receptors are G protein coupled receptors (GPCRs) [38]. 
In humans melatonin exerts its effect via two GPCRs, MT1 and MT2 [39-41], regulating circadian rhythms, 
and participating in the pathomechanism of depression, autism spectrum disorders and neurodegenerative 
disorders [42-44]. Melatonin is also a potent antioxidant [45]. 
 
3. MIGRAINE 
Migraine attacks present with an unilateral throbbing headache accompanied by nausea or vomiting, and 
photo- or phonophobia. Attacks can be divided into four phases (prodrome, aura, headache and postdrome), 
however not every phase is present in every patient [46]. 
 
3.1 Prodrome 
The first phase is the prodorme/ premonitory symptom phase occurring hours or even days before the 
headache attack [47]. Premonitory phase can be present with diverse symptoms including fatigue, mood changes, 
food cravings, concentration problems, sleep disturbances, gastrointestinal disturbances and yawning [48, 49]. 
The prevalence of premonitory symptoms shows great variance among different studies ranging from 33 to 80% 
[46, 50, 51]. Griffin and colleagues have revealed that about two-third of migraine patients are able to predict the 
occurrence of the headache based on premonitory symptoms [52], suggesting that these symptoms are an integral 
part of the migraine attack, not just accompaniments. Two hypotheses emerged attempting to explain the 
mechanisms behind the symptoms, one involving the neurotransmitter dopamine, the other involving the 
hypothalamus. 
The dopamine hypothesis is based on the observation that dopamine agonists produce the same symptoms 
which are present during the premonitory phase, while antagonists, such as domperidone and metoclopramide 
may reverse some of these symptoms and even prevent or moderate the headache [53-55].  
Hypothalamus is the most important nucleus in the human brain involved in the maintenance of homeostasis; 
it regulates endocrine functions, circadian rhythms and harmonizes the function of the parasympathetic and 
sympathetic nervous systems. The diverse functions imply that the impaired operation of the hypothalamus may 
result in very different and at firs glance not related symptoms, resembling migraine premonitory symptoms. 
Furthermore, the clear connection between migraine and the sleep-wake cycle supports the involvement of the 
hypothalamus in the pathomechanism of migraine, but the exact routes of action need to be clarified [56, 57]. 
 
3.2 Aura 
According to the classification of the International Headache Society the two most common forms of 
migraine are migraine without aura and migraine with aura [58]. About one-third of the patient suffering from 
migraine can be classified to the MA group [59], where aura indicates the presence of preceding or 
accompanying transient focal neurological symptoms related to the headache. The aura symptoms are in the 
most cases visual, however sensory, language and motor symptoms can also manifest [60]. A typical aura 
develops within 5 minutes and lasts for 5-60 minutes [58]. 
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Cortical spreading depression (CSD) is considered as the pathophysiological equivalent of migraine aura [61, 
62]. During CSD, a wave of transient depolarization spreads along the cortex accompanied by hyper- and 
hypoperfusion. The spreading velocity of the depolarization wave, 2-5 mm/s, correlates with the spread of the 
visual aura [61, 63]. Zhang and colleagues showed that after focal induction of CSD in rats a long lasting 
activation of meningeal nociceptors occurs with a delay, suggesting that CSD is able to directly activate these 
neurons [64]. However, another study on awake animals did not show pain behaviour after the induction of CSD, 
challenging the theory of CSD being the primary trigger of migraine headache [65]. Knock in models of familial 
hemiplegic migraine (FHM), an autosomal dominantly inherited form of migraine, are more susceptible to CSD, 
suggesting common mechanisms in CSD and FHM development [66]. In the formation of CSD, glutamate 
neurotransmission and NMDA receptors play a crucial role. Agonist of glutamate receptors can trigger CSD 
[67], while the non-competitive NMDA antagonist MK 801 is able to suppress the formation of cortical CSD 
waves [68]. Recent data suggest that different subtypes of NMDA receptors may play diverse roles in the 
formation of CSD, thus subtype specific antagonist may provide a therapeutic approach against CSD [69]. 
 
3.3 Headache phase and postdrome 
For the great part of patients the most debilitating part of the migraine attack is the headache phase. Headache 
can last for 4-72 hours without treatment, with mild or severe strength [58]. The headache is thought to be 
caused by the activation and sensitization of the trigeminovascular system, consisting of the trigeminal nerve and 
innervated areas [70]. The trigeminal nerve is the largest among cranial nerves in humans; it is divided into three 
main divisions, the ophthalmic, maxillary and mandibular branch, of which the ophthalmic gives the sensory 
innervations of the meninges.  
For decades the vascular changes during the migraine attack were thought to be the cause of the headache, 
later a neuronal basic mechanism was suggested, and more recently the neurovascular origin of the headache was 
proposed, however, the primary triggering step in migraine generation is still debated [70]. 
The activation of the primary nociceptive trigeminal afferents leads to peripheral neuropeptide release, 
calcitonin gene-related peptide (CGRP), neurokinin A and substance P are liberated to the perineural space [71, 
72], leading to vasodilatation and plasma protein extravasation and to the activation of mast cells and leukocytes 
collectively termed as neurogenic inflammation [73]. These phenomena are well characterized in animals, 
however in humans only little direct evidence supports the actual presence of neurogenic inflammation during 
the attack [74]. Despite the lack of human data, the importance of neuropeptides, is supported by current drug 
research data focusing on CGRP receptor antagonist and anti-CGRP antibodies [75, 76].  
The continuous activation of the peripheral trigeminal nociceptors leads to peripheral sensitization which 
presents with the worsening of headache during activities increasing intracranial pressure e.g. coughing and in 
the throbbing nature of the headache [77]. 
The next important structure during the process of migraine headache is the caudal part of the spinal 
trigeminal nucleus (TNC), where most of the primary nociceptive afferents project. Activation at the periphery 
proceeds to the TNC, mostly by the aid of glutamate, as its level increases in the TNC after stimulation of the 
first-order trigeminal neurons [78]. Both glutamate [79] and its receptors [80] are present in the trigeminal 
system providing an important modulatory aspect of trigeminal nociception. Activation of the second-order 
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neurons in the TNC can lead to central sensitization at this site [81], which presents in migraineurs during the 
attack as the symptom of allodynia [82]. 
Activation of the trigeminal system spreads forward to thalamic and cortical sites, resulting in the pain 
experienced by migraine patients. 
Imaging studies revealed, that specific brain regions (periaqueductal grey matter, nucleus raphe magnus, 
dorsal raphe nucleus, locus coeruleus) are active during the headache phase, raising the possibility of the 
existence of a migraine generator region [83, 84]. These nuclei are the part of the descending pain modulatory 
system, their activation suggest that the processing and transmission of nociceptive information can be 
dysfunctional in migraine, however these theory needs to be confirmed.  
After the cessation of the migraine pain patients often experience tiredness, difficulties in concentration, 
weakness, dizziness, which can be regarded as the postdrome phase, the least well-defined phase of the migraine 
attack [85, 86].  
 
3.4 Cortical hyperexcitability in migraine 
Cortical hyperexcitability is thought to contribute to the formation of CSD in migraine. The first evidence for 
this hypothesis is that the mutations of the three FHM genes can lead to hyperexcitability. FHM 1 is caused by 
the mutation in the CACNA1A gene located on the chromosome 19p13 coding the α subunit of the voltage-gated 
P/Q type Cav2.1 calcium channel [87]. In knock in animals this mutation results in increased glutamate release 
in the brain [88]. The second type of FHM, FHM II is caused by the mutation in the ATP1A2 gene [89] encoding 
the α2 subunit of Na/K pumps. Mutations of this gene can cause decreased uptake of glutamate and K+ from the 
synaptic cleft. Mutations in the SCN1A gene are responsible for the third type of FHM, FHM III. This gene 
encodes the α1 subunit of the neuronal Nav1.1 voltage-gated sodium channels [90], and leads to accelerated 
recovery of the channel from fast inactivation, leading to a higher firing rate [91]. These data indicate that FHM 
mutations can result in cortical hyperexcitability, suggesting that this phenomenon may also be involved in the 
formation of simple migraine. 
Migraine patients show increased response to various sensory stimuli, further implicating the presence of a 
hyperexcitable state [92]. The lack of habituation to repeated sensory stimuli also confirms the presence of a 
hyper-responsible state even between migraine attacks [93-95]. With positron emission tomography (PET) 
Boulloche and colleagues found that an altered activation of the visual cortex is present in the interictal phase in 
migraineurs compared to controls, confirming the possibility of hyperexcitability with functional imaging [96]. 
Increased glutamate levels can be the basis of the hyperexcitable state; however, measurements of glutamate 
content in migraineurs provided conflicting results. Platelet and plasma measurements of glutamate indicated 
lower or similar levels in migraineurs and controls [97, 98], while in other studies increased basal glutamate 
levels were found [99]. During the attack increased levels of glutamate were found in the cerebrospinal fluid of 
migraine patients [97]. Proton magnetic resonance spectroscopy revealed that a higher glutamate/glutamine ratio 
is present in migrainous women during the interictal phase compared to controls in the occipital cortex [100], 
supporting the presence of altered GLU metabolism in migraine. 
 
4. INVOLVEMENT OF TRYPTOPHAN CATABOLITES IN MIGRAINE 
4.1 Serotonin in migraine 
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The importance of 5HT in migraine pathomechanism was first proposed by Sicuteri and colleagues in 1961 
after detecting increased urinary 5HIAA levels during migraine attacks [101]. Based on these findings numerous 
studies examined peripheral 5HT and 5HIAA levels in plasma and platelets, and their results suggest that no 
alteration is present during the migraine attack in 5HT levels compared to controls [102]. These findings are not 
surprising if we consider that the main source of 5HT and 5HIAA is the gut, where enterochromaffin cells 
synthesize 5HT to fulfil its role in the modulation of peristalsis [103].  
Serotonin is a vasoconstrictor [104], and it was revealed that the peripheral veins of migraineurs show higher 
reactivity to 5HT than controls, furthermore veins of women suffering from migraine react even more to 5HT 
than veins of migrainous men [102] supporting the involvement of 5HT in migraine. 
The measurements of brain 5HT levels and synthetic rates also yielded conflicting results. PET scans with the 
aid of α-[11C] methyl-L tryptophan, a 5HT precursor, revealed an increased 5HT synthesis capacity and also a 
higher brain uptake rate in women with migraine [105]. Using the same method, another study found no 
differences in 5HT synthetic rates between migraineurs and controls during the attack, but interictally a lower 
synthetic rate was found in migraineurs [106]. The same group examined interictal 5HT synthesis in non-
menopausal women, and found no alteration in synthetic rates, however after administration of a 5HT receptor 
agonist, eletriptan a decreased rate was found in migraineurs but not in controls, suggesting an altered regulation 
of 5HT synthesis between attacks [107]. 
Genetic research also attempted to link 5HT to migraine. Studies examining the genetic association between 
migraine and the serotonin synthesizing and metabolizing enzymes TPH, AADA, MAO detected no connection 
[108-111]. Genetic research on 5HT receptors revealed no obvious relation with migraine in the case of 5HT1A 
[112], 5HT2A [113-115] and 5HT2C [116, 117] receptors; however in a small number of affected families 
association was found with 5HT1D receptors [118]. A more promising subject is the 5HT transporter, as its gene 
polymorphisms were found to be associated with migraine in independent meta-analyses [119, 120]. 
In spite of the conflicting result regarding the levels of 5HT in migraineurs, the effectiveness of its agonist, 
triptans in migraine therapy confirms the importance of this compound in disease pathogenesis. Triptans activate 
5HT1B/1D and 5HT1F receptors but many questions are unanswered regarding their mechanism and site of 
action [121, 122]. 
 
4.2 Melatonin in migraine 
Several studies have found decreased nocturnal melatonin levels in migraineurs, especially in women [123, 
124]. In an other study, no difference was found between pain free periods of migraine patients and controls, 
while a decrease of melatonin level was detected in migraineurs during headache attacks [125]. Based on these 
and on other results connecting migraine seasonal variations with melatonin [126], assumption raised, that 
melatonin may play an important role in migraine pathogenesis. Subsequently trials were conducted to examine 
the efficacy of melatonin in migraine therapy, but controversial results were obtained. In an open-label study of 
Peres an colleagues melatonin was effective in migraine prevention [127], while in a randomized, double-blind, 
placebo-controlled crossover study of Alstadhaug and co-workers no beneficiary effect of melatonin was 
detected [56]. Considering the importance of melatonin in the regulation of circadian rhythms and its close 
relation with hypothalamic functions, participation in migraine pathomechanism is highly possible, however the 
exact molecular mechanism and thus possible therapeutic efficacy need to be further confirmed. 
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4.3 Kynurenines in migraine 
Since Sicuteri’s observations about the involvement of 5HT in migraine pathomechanism [101] research 
focused on the 5HT pathway of TRP metabolism, although in the past years the KP’s involvement was also 
confirmed [4, 128].  
TRP was used as an analgesic agent [129], and later on it was revealed that its KP catabolites L-KYN, 
KYNA, AA, XA, PIC and QUIN also possess analgesic properties in the tail-flick and hot-plate tests when 
administered intraperitoneally to rats [130] further supporting their involvement in modulation of nociceptive 
processing and thus in migraine pathomechanism. 
KP catabolites are present both peripherally and centrally in the trigeminal system [21], providing the 
opportunity to modulate trigeminal nociception at various sites. Knyihár-Csillik and colleagues found that after 
electrical stimulation of the trigeminal ganglion, a well characterized model of trigeminal activation and dural 
neurogenic inflammation, KAT immunoreactivity of the cerebral dura mater decreased in rats [131]. These 
results suggest that endogenous KYNA synthesis in the dura may contribute to the modulation of NMDA 
receptor function.  
Several strategies exist to enhance the production of KYNA in the brain and to decrease the amounts of QUIN 
and 3HK, which are thought to be neurotoxic. These involve the application of KYNA precursors, inhibitors of 
KMO, to decrease the synthesis of 3HK and the development of new KYNA-like compounds [132]. These 
approaches were applied also in animal models of trigeminal activation for the evaluation of the involvement of 
KP catabolites in migraine. KYNA passes the blood-brain barrier (BBB) poorly [133], therefore its precursor L-
KYN was applied in animal studies. In the previously mentioned electrical stimulation model the application of 
L-KYN in combination with probenecid was able to decrease the activation of the second order neurons in the 
TNC[134]. Probenecid is an inhibitor of organic acid transport [135], and in joint application with L-KYN it can 
prevent the depletion of KYNA from the central nervous system, raising its levels significantly [136]. 
The same combination was applied in the nitroglycerine induced model (NTG model), where it was also able 
to decrease the activation of the trigeminal system [137]. These results suggest that elevated KYNA levels may 
be protective against trigeminal hyperactivity.  
In the NTG model sensitization processes also occur, [138, 139], presenting with enhanced neuronal nitric 
oxide synthase (nNOS) [140], calmodulin-dependent protein kinase II α (CamKIIα) [141] and decreased CGRP 
content in the TNC [142]. The combination treatment was able to attenuate nNOS [136], while L-KYN by itself 
attenuated the changes of CamKIIα and CGRP levels caused by NTG [143]. 
Two synthetic KYNA amides, 2 (2 N,N dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one 
hydrochloride (KYNA-A1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride 
(KYNA-A2) were also tested in the NTG model. KYNA-A1 was able to mitigate nNOS, CamKIIα and CGRP 
immunoreactivity changes after NTG administration, and KYNA-A2 had the same, but dose dependent effect 
[136, 143, 144]. These results clearly demonstrate the important role of L-KYN and KYNA in trigeminal 
nociceptive processing, and support their important role in migraine pathomechanism. However, the exact routes 
throughout nociceptive modulation occurs are elusive. The general consideration is that both KYNA and its 
derivatives modulate NMDA receptor function, but if their effect takes place peripherally or centrally needs to be 
clarified [136, 143, 144].  
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Studies on experimental CSD in rats conducted by Chauvel and colleagues support the interaction between 
KYNA and NMDA receptors in CSD formation. In their experiments both combined and standalone application 
of L-KYN and probenecid were able to decrease CSD frequency, the combined application having the greatest 
effect compared to control, via increasing the KYNA content in the brain [145]. Their results also show that 
there is a sex-dependence of the effects of L-KYN-probenecid treatment, female rats being more sensitive to it 
[145]. Other results have shown that KYNA administered peripherally can also modulate CSD frequency and 
BBB permeability [146]. Based on these result we can assume, that KYNA has an important role in mitigating 
CSD formation, and therefore it is involved in generation of migraine aura. 
In studies conducted so far with KYNA derivatives the site of application was peripheral. Although the 
purpose of both the combinatory treatment and the application of derivatives are to increase KYNA content in 
the brain, the possible peripheral involvement of KYNA in migraine processes can not be excluded. On the 
periphery both KYNA and other KP catabolites can participate in the formation and modulation of neurogenic 
inflammation (Figure 2). At the level of the secondary trigeminal neurons KYNA and QUIN could modulate 
glutamatergic neurotransmission of nociceptive signals, while at higher levels, at the thalamus and in the cortex 
they may also influence trigeminal pain pathways. In a recent work, Kageneck and colleagues showed that 
KYNA was able to inhibit capsaicin induced CGRP release in the TNC, but had no effect on dural CGRP 
release, supporting the idea, that KYNA may exert altering effects at different sites of the trigeminal system 
[147]. Further knowledge about the KP’s involvement in trigeminal nociceptive processing could lead to a better 
understanding of migraine pathomechanism.  
 
5. CONCLUSIONS 
The aim of the present work was to draw some attention on the role of different tryptophan catabolites, 
especially kynurenine catabolites, in migraine pathomechanism. 5HT have been shown to be involved in the 
nociceptive processing of trigeminal signals, and various aspects of migraine generation, and the other important 
transmitter of the same metabolic pathway, melatonin was also proposed to play a part in these processes. The 
close relationship of the 5HT pathway and the KP of tryptophan degradation suggest, that alterations in one arm 
of the pathway, may influence the other, thus refer to a highly probable involvement of the KP in migraine. 
Research conducted so far in relation with the KP and migraine were focused on KYNA, and results confirm the 
involvement of this compound in migraine related processes. However, further studies are needed to detail the 
possible sites and receptors of effect of KYNA and also the influence of other KP catabolites. 
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Figure 2. Possible routes of action of kynurenic acid and its derivatives 
